BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 12970800)

  • 1. AML with t(8;21) and trisomy 4: possible involvement of c-kit?
    Langabeer SE; Beghini A; Larizza L
    Leukemia; 2003 Sep; 17(9):1915; author reply 1915-6. PubMed ID: 12970800
    [No Abstract]   [Full Text] [Related]  

  • 2. May the correlation between Kit-D816 mutation and AML1-ETO level change the use of prognostic factors in t(8;21) AML?
    Potenza L; Luppi M; Riva G; Ottaviani E; Zucchini P; Morselli M; Volzone F; Forghieri F; Martinelli G; Torelli G
    Leuk Res; 2007 Feb; 31(2):269-71. PubMed ID: 16759701
    [No Abstract]   [Full Text] [Related]  

  • 3. Effects of c-KIT mutations on expression of the RUNX1/RUNX1T1 fusion transcript in t(8;21)-positive acute myeloid leukemia patients.
    Park SH; Chi HS; Cho YU; Jang S; Park CJ
    Leuk Res; 2013 Jul; 37(7):784-9. PubMed ID: 23528260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of bone marrow mast cells in acute myeloid leukemia with t(8;21) (q22;q22); RUNX1-RUNX1T1.
    Pullarkat ST; Pullarkat V; Lagoo A; Brynes R; Weiss LM; Bedell V; Chen W; Huang Q; Gaal K; Weisenburger DD; Kim YS
    Leuk Res; 2013 Nov; 37(11):1572-5. PubMed ID: 24035334
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Importance of c-kit mutation detection method sensitivity in prognostic analyses of t(8;21)(q22;q22) acute myeloid leukemia.
    Wakita S; Yamaguchi H; Miyake K; Mitamura Y; Kosaka F; Dan K; Inokuchi K
    Leukemia; 2011 Sep; 25(9):1423-32. PubMed ID: 21606963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AML1-ETO and C-KIT mutation/overexpression in t(8;21) leukemia: implication in stepwise leukemogenesis and response to Gleevec.
    Wang YY; Zhou GB; Yin T; Chen B; Shi JY; Liang WX; Jin XL; You JH; Yang G; Shen ZX; Chen J; Xiong SM; Chen GQ; Xu F; Liu YW; Chen Z; Chen SJ
    Proc Natl Acad Sci U S A; 2005 Jan; 102(4):1104-9. PubMed ID: 15650049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AML1-ETO9a is correlated with C-KIT overexpression/mutations and indicates poor disease outcome in t(8;21) acute myeloid leukemia-M2.
    Jiao B; Wu CF; Liang Y; Chen HM; Xiong SM; Chen B; Shi JY; Wang YY; Wang JH; Chen Y; Li JM; Gu LJ; Tang JY; Shen ZX; Gu BW; Zhao WL; Chen Z; Chen SJ
    Leukemia; 2009 Sep; 23(9):1598-604. PubMed ID: 19458628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic mastocytosis associated with t(8;21) acute myeloid leukemia in a child: detection of the D816A mutation of KIT.
    Yabe M; Masukawa A; Kato S; Yabe H; Nakamura N; Matsushita H
    Pediatr Blood Cancer; 2012 Dec; 59(7):1313-6. PubMed ID: 22847983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A JAK2-V617F activating mutation in addition to KIT and FLT3 mutations is associated with clinical outcome in patients with t(8;21)(q22;q22) acute myeloid leukemia.
    Iwanaga E; Nanri T; Matsuno N; Kawakita T; Mitsuya H; Asou N
    Haematologica; 2009 Mar; 94(3):433-5. PubMed ID: 19181784
    [No Abstract]   [Full Text] [Related]  

  • 10. Characteristics of t(8;21) acute myeloid leukemia (AML) with additional chromosomal abnormality: concomitant trisomy 4 may constitute a distinctive subtype of t(8;21) AML.
    Nishii K; Usui E; Katayama N; Lorenzo F; Nakase K; Kobayashi T; Miwa H; Mizutani M; Tanaka I; Nasu K; Dohy H; Kyo T; Taniwaki M; Ueda T; Kita K; Shiku H
    Leukemia; 2003 Apr; 17(4):731-7. PubMed ID: 12682630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. N822 mutation of KIT gene was frequent in pediatric acute myeloid leukemia patients with t(8;21) in Japan: a study of the Japanese childhood AML cooperative study group.
    Shimada A; Taki T; Kubota C; Itou T; Tawa A; Horibe K; Tsuchida M; Hanada R; Tsukimoto I; Hayashi Y;
    Leukemia; 2007 Oct; 21(10):2218-9. PubMed ID: 17525721
    [No Abstract]   [Full Text] [Related]  

  • 12. CytCD79a expression in acute leukemia with t(8;21): biphenotypic or myeloid leukemia?
    He G; Wu D; Sun A; Xue Y; Jin Z; Qiu H; Miao M; Tang X; Fu Z; Chen Z
    Cancer Genet Cytogenet; 2007 Apr; 174(1):76-7. PubMed ID: 17350472
    [No Abstract]   [Full Text] [Related]  

  • 13. Acute myeloid leukemia with t(8;21)(q22;q22.1)/RUNX1-RUNX1T1 and KIT Exon 8 mutation is associated with characteristic mastocytosis and dismal outcomes.
    Xie W; Wang SA; Yin CC; Xu J; Li S; Bueso-Ramos CE; Medeiros LJ; Tang G
    Exp Mol Pathol; 2019 Jun; 108():131-136. PubMed ID: 31004601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Poor outcome in a pediatric patient with acute myeloid leukemia associated with a variant t(8;21) and trisomy 6.
    Kelly MJ; Meloni-Ehrig AM; Manley PE; Altura RA
    Cancer Genet Cytogenet; 2009 Feb; 189(1):48-52. PubMed ID: 19167612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A complex karyotype masked a cryptic variant t(8;21)(q22;q22) in a child with acute myeloid leukemia.
    De Figueiredo AF; Liehr T; Bhatt S; Binato R; De Souza MT; De Matos RR; Salles Tde J; Jordy FC; Ribeiro RC; Abdelhay E; Silva ML
    Leuk Lymphoma; 2011 Aug; 52(8):1593-6. PubMed ID: 21657952
    [No Abstract]   [Full Text] [Related]  

  • 16. Complex t(8;13;21)(q22;q14;q22)--a novel variant of t(8;21) in a patient with acute myeloid leukemia (AML-M2).
    Udayakumar AM; Alkindi S; Pathare AV; Raeburn JA
    Arch Med Res; 2008 Feb; 39(2):252-6. PubMed ID: 18164974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. JAK2V617F as progression marker in CMPD and as cooperative mutation in AML with trisomy 8 and t(8;21): a comparative study on 1103 CMPD and 269 AML cases.
    Schnittger S; Bacher U; Kern W; Haferlach T; Haferlach C
    Leukemia; 2007 Aug; 21(8):1843-5. PubMed ID: 17443220
    [No Abstract]   [Full Text] [Related]  

  • 18. Submicroscopic deletions in an acute myeloid leukemia case with a four-way t(8;11;16;21).
    Albano F; Specchia G; Anelli L; Liso A; Zagaria A; Santoro A; Mirto S; Liso V; Rocchi M
    Leuk Res; 2005 Jul; 29(7):855-8. PubMed ID: 15927680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence of AML1/ETO fusion transcripts in patients entered into the MRC AML trials. MRC Adult Leukaemia Working Party.
    Langabeer SE; Walker H; Rogers JR; Burnett AK; Wheatley K; Swirsky D; Goldstone AH; Linch DC
    Br J Haematol; 1997 Dec; 99(4):925-8. PubMed ID: 9432044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Kasumi-1 cell line: a t(8;21)-kit mutant model for acute myeloid leukemia.
    Larizza L; Magnani I; Beghini A
    Leuk Lymphoma; 2005 Feb; 46(2):247-55. PubMed ID: 15621809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.